Epstein–Barr virus peptide–Human Leukocyte Antigen complex (EBV pMHC)

Epstein–Barr virus (EBV) peptide–Human Leukocyte Antigen (HLA) complexes are essential molecular structures formed when EBV-derived antigenic peptides are processed and presented on the surface of host cells by HLA molecules. These complexes are the primary targets for the adaptive immune system, specifically CD8+ cytotoxic T lymphocytes (CTLs), which recognize the peptide-MHC assembly via their T-cell receptors (TCRs) to initiate the destruction of infected or transformed cells (Source: PubMed, PMID: 31435325). In EBV-associated diseases, including various lymphomas and nasopharyngeal carcinoma, the virus persists in a latent state, expressing specific proteins like EBNA1, LMP1, and LMP2, whose peptides are presented by HLA to maintain a balance between viral persistence and immune surveillance (Source: Nature Reviews Cancer, doi:10.1038/nrc1416). Therapeutic interventions targeting these complexes include adoptive T-cell therapies, such as Tabelecleucel, and TCR-engineered T cells designed to enhance the immune response against EBV-positive malignancies (Source: EMA, Ebvallo Assessment Report). Additionally, these complexes are being investigated as targets for TCR-like antibodies and peptide-based vaccines aimed at preventing or treating EBV-related conditions like post-transplant lymphoproliferative disorder and potentially multiple sclerosis (Source: Science, doi:10.1126/science.abj8222).

Other names

EBV peptide–MHC complexEpstein-Barr virus antigen-HLA complexEBV-specific pMHCEBV pMHC

Recognition of the specific peptide-HLA complex by T-cell receptors (TCRs) or TCR-mimetic molecules, leading to targeted lysis of the presenting cell through the release of perforins and granzymes.